LOWELL, Mass.--(BUSINESS WIRE)--Alcyone Lifesciences, Inc., a privately-held medical device company developing products for the treatment of difficult neuropathological conditions, announced the appointment of Michael Rogawski, MD., PhD., of University of California, Davis to its clinical and scientific advisory board.
“Throughout his career, Dr. Rogawski has been in the forefront of bringing novel and effective treatment for hard to treat seizures and epilepsy,” said PJ Anand, Founder and Chief Executive Officer, Alcyone Lifesciences. “His research continues to drive significant advancement in the field and we look forward to his contribution to Alcyone.”
“Alcyone’s technology platform is unique in that it has the potential to significantly improve certain seizure and epileptic conditions and offer new possibilities to help patients with this debilitating condition. I am looking forward to working with the talented Alcyone team,” said Dr. Rogawski.
Dr. Rogawski is an internationally recognized expert on treatments for seizures and epilepsy. He is currently professor of neurology and member of the Center for Neuroscience at the University of California, Davis. Until 2006, he was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. Dr. Rogawski’s research encompasses cellular neurophysiological studies of ion channels and animal seizure models. He was the first to investigate convection-enhanced delivery of antiseizure agents in the treatment of epilepsy. In recognition of his research contributions, Dr. Rogawski received the NIH Director’s Award and the Epilepsy Research Award from the American Society for Pharmacology and Experimental Therapeutics. He presented the William G. Lennox Lecture of the American Epilepsy Society. Dr. Rogawski received his bachelor’s degree in biophysics from Amherst College, and M.D. and Ph.D. in pharmacology from Yale. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology at NINDS, he completed residency training in neurology at Johns Hopkins.
About Alcyone Lifesciences
Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held medical device company focused on development of novel treatment modalities for difficult neurological conditions. The Company's patented technology platform is based on a uniquely engineered amalgamation of microfabrication technologies along with advanced biomedical engineering with core product focus on targeted drug therapy and hydrocephalus. Alcyone's team of scientists, physicians and advisers includes recognized leaders in the field of neurology and neurosurgery. For more information, please visit www.alcyonels.com.